Francois Bertucci
Elite in Inflammatory Breast Cancer

Francois Bertucci

Marseille, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Inflammatory Breast Cancer
Marseille, FR 
OverviewLocationsClinical Research

Overview

Francois Bertucci practices in Marseille, France. Mr. Bertucci and is rated as an Elite expert by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Inflammatory Breast Cancer, Adult Soft Tissue Sarcoma, Breast Cancer, Hysterectomy, and Oophorectomy.

His clinical research consists of co-authoring 492 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 61 articles in the study of Inflammatory Breast Cancer.

Gender
Male

Locations

Marseille, 13000, France
Other Locations
Hôpital Cochin Port Royal
Vandoeuvre-les-nancy, France
Lyon, France
Aix-en-provence, France
Paris, France
Saint-etienne, 13009, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

MegaMOST - a Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /characteristics in Advanced / Metastatic Tumors.
MegaMOST - a Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /characteristics in Advanced / Metastatic Tumors.
Enrollment Status: Recruiting
Publish Date: December 12, 2024
Intervention Type: Drug
Study Drugs: HDM201, Ribociclib, Cabozantinib, Alectinib
Study Phase: Phase 2
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2024
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and Sunitinib
A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and Sunitinib
Enrollment Status: Completed
Publish Date: June 18, 2024
Intervention Type: Other, Drug
Study Drug: Lenvatinib
Study Phase: Phase 2
A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
Enrollment Status: Completed
Publish Date: January 05, 2024
Intervention Type: Drug
Study Drug: Imatinib Maintenance
Study Phase: Phase 3
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Genetic
Study Phase: Not Applicable
Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
Enrollment Status: Unknown
Publish Date: May 05, 2021
Intervention Type: Drug
Study Drugs: MK3475, Pembrolizumab, Endoxan, Cyclophosphamide, G100, Metronomic
Study Phase: Phase 2
Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors-PERMED01-IPC 2014-003
Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors-PERMED01-IPC 2014-003
Enrollment Status: Unknown
Publish Date: January 22, 2021
Intervention Type: Other, Procedure
Study Phase: Not Applicable
Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas
Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas
Enrollment Status: Completed
Publish Date: January 31, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

492 Total Publications

Multiscale Modeling Uncovers Macrophage Infiltration and TNF-α Signaling Networks for Targeting in Inflammatory Breast Cancer Tumor Emboli.
Multiscale Modeling Uncovers Macrophage Infiltration and TNF-α Signaling Networks for Targeting in Inflammatory Breast Cancer Tumor Emboli.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bertucci's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 8 Advanced Conditions
View All 47 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile